Description
Quest Diagnostics’ $119 Lab Tests: A New Consumer Healthcare Growth Catalyst!
Quest Diagnostics Incorporated reported third quarter 2026 results reflecting a 10% increase in consolidated revenues to $3.1 billion, with diagnostic information services revenues rising 10.2% organically. This growth was supported by increased volumes across physician, hospital, and consumer channels, with total requisition volumes growing 14.5%, and an organic volume gain of 14.4%. Corewell Health and Fresenius Medical Care partnerships contributed significantly to these volume increases, accounting for 9.5% of the quarter’s volume. When excluding these relationships, volume grew by 5%, indicating underlying demand expansion. Revenue per requisition declined 4.2% due to the business mix involving these partnerships but was up 1.7% on a comparable basis outside of this effect. Pricing was generally flat, consistent with expectations. Operating income increased to $479 million, or 15.5% of revenues, improving both in absolute terms and margin percentage from prior year.



